• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).

作者信息

de Tullio P, Delarge J, Pirotte B

机构信息

Department of Medicinal Chemistry, University of Liège, C.H.U., Tour 4-Niveau, 5, Avenue de 1'Hôpital 1, Liège, B-4000, Belgium.

出版信息

Curr Med Chem. 1999 Jun;6(6):433-55.

PMID:10213792
Abstract

During the last few years, cholecystokinin (CCK) has emerged as an important hormone. This polypeptide has been located either in peripheral tissues such as the gastro-intestinal tract and the pancreas as well as in the central nervous system. High affinity CCK receptors are divided in two main subtypes: the CCK-A (A for (A for "alimentary") and the CCK-B (B for "brain") receptors. The latters are currently associated with the gastrin receptors. Since CCK is involved in many different biological processes such as gut function, digestive processes, control of feeding behaviour and neurotransmitter release, the therapeutical potential of cholecystokinin receptor ligands seems to be extremely broad and promising. Several families of CCK receptor ligands (peptides, peptidomimetics, peptoids or non-peptides) were prepared during the last twenty years. The main goal of these researches was to improve agonistic or antagonistic potency but also to find selective compounds for a specific CCK receptor subtype. This review presents the recent developments (since 1995) in the chemistry of CCK receptor ligands.

摘要

相似文献

1
Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).
Curr Med Chem. 1999 Jun;6(6):433-55.
2
Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.胆囊收缩素B/胃泌素受体的小型合成配体可模拟内源性肽类激素的功能。
Yale J Biol Med. 1998 May-Aug;71(3-4):337-46.
3
CCK receptor antagonists.胆囊收缩素受体拮抗剂
Gen Pharmacol. 1998 Oct;31(4):519-24. doi: 10.1016/s0306-3623(98)00078-0.
4
Therapeutic and chemical developments of cholecystokinin receptor ligands.胆囊收缩素受体配体的治疗学与化学进展
Expert Opin Investig Drugs. 2000 Jan;9(1):129-46. doi: 10.1517/13543784.9.1.129.
5
Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).胆囊收缩素-A和胆囊收缩素-B/胃泌素受体激活的不同要求:用胆囊收缩素四肽(30-33)的C末端酰肼类似物进行的研究
Mol Pharmacol. 1989 Dec;36(6):881-6.
6
Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands.胆囊收缩素类肽配体中受体选择性和功能活性的修饰。
J Med Chem. 1995 Aug 18;38(17):3384-90. doi: 10.1021/jm00017a022.
7
Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists.一些非肽类胆囊收缩素拮抗剂的定量构效关系研究
Bioorg Med Chem. 1999 Jun;7(6):1127-30. doi: 10.1016/s0968-0896(99)00013-9.
8
Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.新型强效选择性胃泌素/缩胆囊素-B受体拮抗剂(R)-1-[2,3-二氢-1-(2'-甲基苯甲酰基)-2-氧代-5-苯基-1H-1,4-苯并二氮杂卓-3-基]-3-(3-甲基苯基)脲(YM022)的体内外药理学特性
J Pharmacol Exp Ther. 1994 May;269(2):725-31.
9
Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.使用高架十字迷宫试验装置分析PVG有帽大鼠和斯普拉格-道利大鼠对胆囊收缩素(CCK)受体介导药物行为的品系差异。
Neurosci Lett. 2004 Apr 1;358(3):215-9. doi: 10.1016/j.neulet.2004.01.027.
10
Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex.在小鼠和大鼠大脑皮层进行的放射性配体结合试验中,对选定的CCKB/胃泌素受体拮抗剂的行为分析。
Br J Pharmacol. 1999 Mar;126(6):1496-503. doi: 10.1038/sj.bjp.0702448.

引用本文的文献

1
1,5-Disubstituted 1,2,3-Triazoles as Amide Bond Isosteres Yield Novel Tumor-Targeting Minigastrin Analogs.作为酰胺键生物电子等排体的1,5-二取代-1,2,3-三唑产生新型肿瘤靶向性小胃泌素类似物。
ACS Med Chem Lett. 2021 Mar 16;12(4):585-592. doi: 10.1021/acsmedchemlett.0c00636. eCollection 2021 Apr 8.
2
A sucrose-derived scaffold for multimerization of bioactive peptides.蔗糖衍生的支架用于生物活性肽的多聚化。
Bioorg Med Chem. 2011 Nov 1;19(21):6474-82. doi: 10.1016/j.bmc.2011.08.053. Epub 2011 Aug 27.
3
Cholecystokinin facilitates glutamate release by increasing the number of readily releasable vesicles and releasing probability.
胆囊收缩素通过增加易释放囊泡的数量和释放概率来促进谷氨酸的释放。
J Neurosci. 2010 Apr 14;30(15):5136-48. doi: 10.1523/JNEUROSCI.5711-09.2010.
4
Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.开发具有治疗潜力的胆囊收缩素(CCK)/胃泌素受体配体的进展。
Curr Opin Pharmacol. 2007 Dec;7(6):583-92. doi: 10.1016/j.coph.2007.09.011. Epub 2007 Nov 9.
5
Bidirectional modulation of GABAergic transmission by cholecystokinin in hippocampal dentate gyrus granule cells of juvenile rats.胆囊收缩素对幼年大鼠海马齿状回颗粒细胞GABA能传递的双向调节作用
J Physiol. 2006 Apr 15;572(Pt 2):425-42. doi: 10.1113/jphysiol.2005.104463. Epub 2006 Feb 2.